
<0.01) and from 4.8 to 0.6 in the surgery group (P <0.001) (Sell et al. 2014a). Therefore,
the Society for Vascular Surgery recommends against a three-month trial of conservative
therapy prior to intervention for patients with C2 and C3 disease (Gloviczki et al. 2024a).
 In the landmark ESCHAR trial, patients with C5-C